A Randomized Phase II Study of Sequencing Abiraterone Acetate and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 24 Jan 2019
Price : $35 *
At a glance
- Drugs Abiraterone acetate (Primary) ; Enzalutamide (Primary) ; Prednisone
- Indications Adenocarcinoma; Bone metastases; Prostate cancer
- Focus Therapeutic Use
- 15 Jan 2019 Planned primary completion date changed from 1 Jul 2018 to 1 Jul 2019.
- 31 Aug 2018 Biomarkers information updated
- 13 Jul 2018 Planned End Date changed from 1 Jul 2018 to 1 Jul 2019.